Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the stethoscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim interviews Dr James Garner, CEO & Executive Director of Kazia Therapeutics (ASX:KZA).

Kazia (formerly Novogen) is an oncology focused drug developer with a particular focus on difficult-to-treat brain cancers.

The company’s lead drug candidate, GDC-0084 aims to deliver therapies across the blood brain barrier, the body’s natural mechanism to protect the brain from foreign agents.

Kazia also has a preclinical drug candidate to treat ovarian cancer, called Cantrixil.

Both GDC-0084 and Cantrixil have been granted ‘orphan drug’ designation by the US Food and Drug Administration, which provides for benefits such as tax breaks and seven-year marketing exclusivity.

Kazia shares have soared 50 per cent in the last few weeks ahead of the expected release of phase 11 results for the GDC-0084 program.

Tune in to hear the pair discuss beating glioblastoma, crossing the blood-brain barrier and the joys of receiving a gong from Jacinda Ardern.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!

Featured Companies

You might be interested in